GlassScriptPhysician profile
Matthew J Hadeed
NPI 1205265071
$450.71
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.09 · 2020: $129 · 2021: $300.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $97.61 | 2020-2021 | |
| Tris Pharma INC | $91.90 | 2021 | |
| Welch Allyn | $66.37 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.03 | 2021 | |
| Cranial Technologies, INC | $37.65 | 2019-2021 | |
| Adlon Therapeutics L.P. | $32.85 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $21.68 | 2021 | |
| Kaleo, INC. | $20.22 | 2021 | |
| Merck Sharp & Dohme LLC | $17.40 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Hadeed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.